Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Sheng

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Clinical Pharmacology and Therapeutics|February 26, 2019
Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development StrategiesLi Zhou, Mitsuo Higashimori, Kai Shen, et al.
Clinical Pharmacology and Therapeutics|December 20, 2024
Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft-Versus-Host DiseaseYan-Ou Yang, Victor Sokolov, Alina Volkova, et al.
The Oncologist|May 4, 2019
A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid TumorsYuxiang Ma, Wenfeng Fang, Yang Zhang, et al.
British Journal of Haematology|July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growthMeletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Clinical Pharmacology and Therapeutics|February 26, 2019
Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development StrategiesLi Zhou, Mitsuo Higashimori, Kai Shen, et al.
Clinical Pharmacology and Therapeutics|December 20, 2024
Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft-Versus-Host DiseaseYan-Ou Yang, Victor Sokolov, Alina Volkova, et al.
The Oncologist|May 4, 2019
A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid TumorsYuxiang Ma, Wenfeng Fang, Yang Zhang, et al.
British Journal of Haematology|July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growthMeletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Pageof 3